From Copper Accumulation to Personalized Medicine: Understanding Wilson Disease and Looking Ahead to Future Directions
GBP Proceedings Series · 23.07.2026 · 28 · 170-179
DOI: 10.70088/066mqc68 ↗Kurz gefasst
Fachartikel in der Zeitschrift GBP Proceedings Series, online erschienen am 23.07.2026. Verfasst von Chenyu Zhang.
Abstract (Originalsprache)
Wilson disease (WD) is an autosomal recessive hereditary disorder of copper metabolism caused by mutations in the ATP7B gene on chromosome 13. This paper systematically reviews the complete research landscape of WD, covering its discovery history, pathogenic mechanisms, epidemiology, clinical subtypes, current therapeutic strategies, and future advances in personalized medicine. Epidemiological data reveal an uneven global distribution of WD, with a markedly higher prevalence in Asia than in Europe and North America. The disease primarily onsets between the ages of 5 and 35, and is clinically categorized into three major subtypes: hepatic, neurological, and psychiatric. Multi-system involvement frequently leads to missed or misdiagnosis. Loss-of-function mutations in ATP7B impair hepatic copper transport and biliary excretion, resulting in massive copper accumulation in the liver. Excess copper triggers overproduction of reactive oxygen species (ROS), which initiates lipid peroxidation, protein and nucleic acid damage, mitochondrial dysfunction, cuproptosis, inflammatory cascades, and hepatic fibrosis. Copper subsequently leaks into systemic circulation and deposits in the brain, cornea, kidneys, myocardium, and other organs, causing multi-organ lesions. Current clinical management relies on long-term copper elimination therapy, including low-copper dietary modification, copper chelators (D-penicillamine and trientine), and zinc salts. Liver transplantation is reserved for patients with end-stage liver disease. Nevertheless, conventional treatments are limited by adverse drug reactions, irreversible neurological damage, and lifelong medication requirements. Future personalized medicine strategies center on curative gene therapies such as AAV-mediated gene repair, CRISPR gene editing, and stem cell therapy. Newborn screening combining dried blood spot ATP7B peptide detection and genomic sequencing enables early diagnosis. At present, gene therapy faces multiple bottlenecks including limited vector packaging capacity, host immune rejection, diminished efficacy in pediatric patients due to liver proliferation, and off-target effects. As a classic research model for copper metabolism disorders, Wilson disease also serves as a critical paradigm for rare monogenic diseases advancing toward early screening, precise stratification, and curative gene-based individualized therapy.
Zitieren
APA
Zhang, C. (2026). From Copper Accumulation to Personalized Medicine: Understanding Wilson Disease and Looking Ahead to Future Directions. GBP Proceedings Series, 28, 170-179. https://doi.org/10.70088/066mqc68
Vancouver
Zhang C. From Copper Accumulation to Personalized Medicine: Understanding Wilson Disease and Looking Ahead to Future Directions. GBP Proceedings Series. 2026;28:170-179. doi:10.70088/066mqc68
BibTeX
@article{Zhang2026,
author = {Zhang, Chenyu},
title = {From Copper Accumulation to Personalized Medicine: Understanding Wilson Disease and Looking Ahead to Future Directions},
journal = {GBP Proceedings Series},
year = {2026},
volume = {28},
pages = {170--179},
doi = {10.70088/066mqc68}
}
EUVIMED